Latest News

Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity

Dr. Keith Vossel, Professor of Neurology and Director of the UCLA Easton Center, published the highly anticipated results of a phase 2a randomized, placebo-controlled clinical trial of the anti-seizure medication levetiracetam for Alzheimer’s disease. This study was published in JAMA Neurology. The clinical trial showed that levetiracetam improves cognitive functions in Alzheimer’s patients with epileptic activity. The publication was featured in UCLA Health News and other news resources such as Newswise, Science Daily, News Medical, and more.  

New Research Suggests that Covid-19 Could Lead to Cognitive Decline

Dr. Keith Vossel, Professor of Neurology,and Director of the Mary S. Easton Center for Alzheimer's Research and Care at UCLA, David Geffen School of Medicine, was interviewed for a July 29th The Washington Post article suggesting that coronavirus infection may lead to cognitive decline.

What Is the New Alzheimer’s Disease Medication – and Who Should Get It?

Dr. Keith Vossel, Professor of Neurology, and Director of the Mary S. Easton Center for Alzheimer's Research and Care at UCLA, David Geffen School of Medicine, was featured in a June 15 UCLA Health article explaining the science behind the newly FDA approved Alzheimer's disease medication, Aduhelm (aducanumab).

Health Professionals